Cutaneous Lupus Erythematosus Market Insight & Forecast Reveals USD 1.2 Billion Growth Potential by 2032 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cutaneous Lupus Erythematosus Market Insight, Epidemiology And Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

This comprehensive analysis offers a profound understanding of Cutaneous Lupus Erythematosus, its historical and forecasted epidemiology, and market trends across the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, Japan, and China.

Cutaneous Lupus Erythematosus, a chronic autoimmune disease affecting the skin, requires long-term monitoring due to its chronic and relapsing nature. The treatment revolves around topical and systemic therapies, aimed at reducing disease activity and cosmetic damage. The report emphasizes the importance of patient education on risk factors, protective measures, and long-term follow-ups to improve treatment outcomes.

With a multifactorial pathogenesis involving genetic and environmental factors, Cutaneous Lupus Erythematosus is categorized into three main entities: acute, subacute, and chronic. Diagnosis requires careful classification through physical exams, laboratory studies, antibody serology, histology, and direct immunofluorescence, while excluding systemic disease.

In 2022, the Cutaneous Lupus Erythematosus market in the 7MM and China was approximately USD 580 million, expected to reach USD 1.2 billion by 2032. The United States held the highest market share in 2022, followed by China. Off-label and generic therapies play a significant role in the market, offering first-mover advantages.

The report sheds light on emerging drugs, such as BDCA2 protein inhibitors, dendritic cell inhibitors, and TYK2 kinase inhibitors, which are expected to expand the treatment landscape. Notably, Biogen’s litifilimab and Bristol Myers Squibb’s deucravacitinib will lead the Cutaneous Lupus Erythematosus market in the forecast period.

The report provides a ten-year patient-based forecast, detailed epidemiology segmentation, and key cross-competition analysis. It also examines the current and emerging therapies and their impact on the treatment landscape.

Key Highlights

• The treatment of Cutaneous lupus erythematosus is centered upon formulating a regimen of topical and systemic therapies designed to reduce disease activity and minimize cosmetic damage. Sun avoidance and sunscreen are important preventative measures proven to minimize Cutaneous lupus erythematosus exacerbations.
• Cutaneous lupus erythematosus requires long-term disease monitoring due to its chronic and relapsing course.
• Patient education on the risk factors, protective measures, and the necessity of a long-term follow-up is a basis for a better treatment outcome.
• The pathogenesis of cutaneous lupus erythematosus is multifactorial, with an interplay between genetic and environmental factors. Immune dysregulation and aberrant cell signaling pathways through cytokine cascades are also implicated
• It is categorized into three main entities: acute cutaneous lupus erythematosus (ACLE), subacute CLE, and chronic cutaneous lupus erythematosus (CCLE). CCLE encompasses discoid LE (DLE), LE profundus (LEP), chilblain LE (CHLE), and LE tumidus (LET).
• Diagnosis of these diseases requires proper classification of the subtype through a combination of a physical exam, laboratory studies, histology, antibody serology, and occasionally direct immunofluorescence while ensuring to exclude systemic disease.
• Presentation of Overlapping clinical symptoms among cutaneous lupus erythematosus subtypes and with other skin diseases like cancer etc., led to a lower diagnosis rate.
• Advancements in research and development, coupled with the relay of scientific information about disease pathophysiology and the introduction of new diagnostic techniques, present an optimistic future in terms of cutaneous lupus erythematosus diagnosis.
• In 2022, the total market size of Cutaneous lupus erythematosus in the 7MM and China was ~USD 580 million, expected to reach ~USD 1,260 million by 2032. In the total Cutaneous lupus erythematosus market size, the United States accounted for the highest market size in 2022, followed by China.
• Off-label and generic therapies constitute almost a share of the cutaneous lupus erythematosus market, providing an opportunity to gain a first-mover advantage.
• As of now, no drug has been specifically approved for CLE. It is due to the challenges associated with trials on lupus. High placebo response rates due to background therapies make interpreting trial endpoints difficult.
• Among emerging drugs, BDCA2 protein inhibitors, dendritic cell inhibitors, and TYK2 kinase inhibitors will be expanding the treatment landscape of CLE.
• Out of these emerging therapies, Biogen’s litifilimab and Bristol Myers Squibb deucravacitinib will be the leading drugs in the Cutaneous lupus erythematosus market in our forecast period.
• Litifilimab, developed by Biogen, is a humanized IgG1 monoclonal antibody targeting BDCA2 and is being investigated for the potential treatment of SLE and CLE. Currently, it is being developed in Phase II/III trials to treat CLE. The estimates it will garner sales of approximately USD 175 million in the 7MM and China by 2032.
• Approved targeted therapies are needed for an hour to cater to treatment for the growing diagnosed prevalent pool of cutaneous lupus erythematosus.
• Emerging therapies such as Biogen’s litifilimab (BIIB059), Horizon Therapeutics’s daxdilimab (VIB7734), Bristol-Myers Squibb’s SOTYKTU (deucravacitinib) have the potential to create a significant positive shift in the cutaneous lupus erythematosus market size in our forecast period.

Cutaneous Lupus Erythematosus Report Insights

• Patient Population
• Therapeutic Approaches
• Cutaneous Lupus Erythematosus Pipeline Analysis
• Cutaneous Lupus Erythematosus Market size and Trends
• Existing and Future Market Opportunities

Cutaneous Lupus Erythematosus Report Key Strengths

• Ten Years Patient-based Forecast
• The 7MM and China coverage
• Cutaneous Lupus Erythematosus Epidemiology Segmentation
• Key Cross Competition
• Attribute Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Cutaneous Lupus Erythematosus Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

For more information about this report visit https://www.researchandmarkets.com/r/uu6zdl

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900